Corcept Highlights BELLA Phase 2 Data as Lifyorli Triplet Shows 7.2-Month Median PFS in Platinum-Resistant Ovarian Cancer
Market Chameleon (Mon, 26-Oct 9:41 AM)
Corcept rallies as EU panel backs relacorilant for platinum-resistant ovarian cancer, with EC decision eyed in Q4 2026
Market Chameleon (Mon, 21-Sep 11:39 AM)
Corcept gains EU regulatory momentum as CHMP backs relacorilant combo for platinum-resistant ovarian cancer
Market Chameleon (Fri, 18-Sep 10:27 AM)
